98%
921
2 minutes
20
Background: Chronic obstructive pulmonary disease affects nearly 400 million worldwide - over a million in the United Kingdom - and is the third leading cause of death. However, there is limited understanding of what prompts a diagnosis, how long this takes from symptom onset and the different approaches to clinical management by primary care professionals.
Objectives: Map out the clinical management and National Health Service contacts from symptom presentation to chronic obstructive pulmonary disease diagnosis and first acute exacerbation of chronic obstructive pulmonary disease in three time periods; construct risk prediction for first acute exacerbation of chronic obstructive pulmonary disease.
Design: Retrospective cohort study and cross-sectional survey.
Setting: Primary care.
Participants: Patients with incident chronic obstructive pulmonary disease aged > 35 years in England.
Interventions: None.
Main Outcome Measures: First acute exacerbation of chronic obstructive pulmonary disease.
Data Sources: Clinical Practice Research Datalink Aurum; new online survey.
Results: Forty thousand five hundred and seventy-seven patients were diagnosed between April 2006 and March 2007 (cohort 1), 48,249 between April 2016 and March 2017 (cohort 2) and 4752 between March and August 2020 (cohort 3). The mean (standard deviation) age was 68.3 years (12.0); 47.3% were female. Around three-quarters were diagnosed in primary care, with a slight fall in cohort 3. Compliance with National Institute for Health and Care Excellence diagnostic guidelines was slightly higher in cohorts 2 and 3 for all patients; 35.8% (10.0% in the year before diagnosis) had all four elements met for all cohorts combined. Multilevel modelling showed considerable between-practice variation in spirometry. The survey on the charity website had 156 responses by chronic obstructive pulmonary disease patients. Many respondents had not heard of the condition, hoped the symptoms would go away and identified various healthcare-related barriers to earlier diagnosis. Clinical Practice Research Datalink analysis showed notable changes in post-diagnosis prescribing from cohort 1 to 2, such as increases in long-acting muscarinic antagonist (21.7-46.3%). Triple therapy rose from 2.9% in cohort 2 to 11.1% in cohort 3. Documented pulmonary rehabilitation rose from just 0.8% in cohort 1 to 13.7% in cohort 2 and 20.9% in cohort 3. For all patients combined, the median time to first acute exacerbation of chronic obstructive pulmonary disease in patients who had one was 1.4 years in cohorts 1 and 2. Acute exacerbation of chronic obstructive pulmonary disease prediction models identified some consistent predictors, such as age, deprivation, severity, comorbidities, post-diagnosis spirometry and annual review. Models without post-diagnosis general practitioner actions had a -statistic of around 0.70; the highest -statistic was 0.81, for cohort 2 with post-diagnosis general practitioner actions and 6-month follow-up. All models had good calibration. The three most important predictors in terms of their population attributable risks were being a current smoker and offered smoking cessation advice (32.8%), disease severity (30.6%) and deprivation (15.4%). The highest population attributable risks for variables with adjusted hazard ratios < 1 were chronic obstructive pulmonary disease review (-27.3%) and flu vaccination (-26.6%).
Limitations: Symptom recording and chronic obstructive pulmonary disease diagnosis vary between practice; predicted forced expiratory volume in 1 second had many missing values.
Conclusions: There has been some improvement over time in chronic obstructive pulmonary disease diagnosis and management, with large changes in prescribing, though patient and system barriers to further improvement exist. Data available to general practitioners cannot generate risk prediction models with sufficient accuracy.
Future Work: It will be important to expand the COVID-era cohort with longer follow-up and augment general practitioner data for better prediction.
Study Registration: This study is registered as Researchregistry.com: researchregistry4762.
Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme (NIHR award ref: 17/99/72) and is published in full in ; Vol. 12, No. 43. See the NIHR Funding and Awards website for further award information.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3310/CGTR6370 | DOI Listing |
JAAPA
September 2025
Clay W. Walker is an assistant professor of family medicine at Mayo Clinic in Phoenix, AZ; director of didactic education and an assistant professor in the PA program at A.T. Still University in Mesa, AZ; and an adjunct assistant professor at Rush University in Chicago, IL. Thomas Hartman is directo
Hemoptysis, defined as the expectoration of blood originating from the lower respiratory tract, is a clinical symptom with a wide differential diagnosis that ranges from benign to life-threatening causes. Common causes vary by geographic region and care setting, with respiratory infections, malignancy, bronchiectasis, and chronic obstructive pulmonary disease being predominant in resource-rich countries and tuberculosis remaining the leading cause in resource-limited areas. Though most cases are mild and self-limited, hemoptysis can be a life-threatening medical emergency; these cases are associated with a mortality exceeding 50%, primarily due to asphyxia.
View Article and Find Full Text PDFRadiology
September 2025
Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Plc, Box 1234, New York, NY 10029.
Background The prognostic value of baseline visual emphysema scoring at low-dose CT (LDCT) in lung cancer screening cohorts is unknown. Purpose To determine whether a single visual emphysema score at LDCT is predictive of 25-year mortality from all causes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease (CVD). Materials and Methods In this prospective cohort study, asymptomatic adults aged 40-85 years with a history of smoking underwent baseline LDCT screening for lung cancer between June 2000 and December 2008.
View Article and Find Full Text PDFGen Physiol Biophys
September 2025
Pneumology Department, Zigong First People's Hospital, Zigong, China.
Chronic obstructive pulmonary disease (COPD) is characterized by airway remodeling and inflammation. Cigarette smoke extract (CSE) induces apoptosis, inflammation, and oxidative stress in COPD. Tripterygium glycosides (TG) are an active compound found in the root extracts of Tripterygium wilfordii Hook F (TWHF) that possesses anti-inflammatory and immunosuppressive effects.
View Article and Find Full Text PDFJ Investig Med
September 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hebei North University, Qiaoxi District, Zhangjiakou, China.
BackgroundWe explored the potential impact of testosterone treatment in a male rat model of chronic obstructive pulmonary disease (COPD). Our study focused on evaluating the potential decrease in the expression and activation of matrix metalloproteinase-9 (MMP-9) and fibroblast growth factor-23 (FGF-23) induced by COPD.MethodsWistar rats were randomly assigned to one of three groups: control, COPD, or testosterone treatment.
View Article and Find Full Text PDFTher Adv Respir Dis
September 2025
Department of Respiratory Medicine, Shangyu People's Hospital of Shaoxing, Zhejiang, China.
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition associated with increased morbidity and mortality, particularly during respiratory infections such as influenza. The interaction between COPD and influenza is multifaceted, involving compromised immune responses, chronic inflammation, and impaired lung function. Influenza infection can exacerbate COPD, leading to acute exacerbations, hospitalizations, and higher mortality.
View Article and Find Full Text PDF